ストックスクリーナーアプリを入手
9.50
3.36%
-0.33
プレマーケット:
9.38
-0.12
-1.26%
前日終値:
$9.83
開ける：
$9.72
24時間の取引高:
1.77M
Relative Volume:
0.97
時価総額：
$1.23B
収益：
$727.33M
当期純損益:
$-108.03M
株価収益率:
-11.26
EPS:
-0.844
ネットキャッシュフロー:
$-21.78M
1週間 パフォーマンス:
-4.71%
1か月 パフォーマンス:
-22.83%
6か月 パフォーマンス:
+7.83%
1年 パフォーマンス:
-4.90%
1日の値動き範囲:
$9.29
$9.82
1週間の範囲:
$9.29
$10.23
52週間の値動き範囲:
$4.72
$13.74
Neogenomics Inc Stock (NEO) Company Profile
Compare NEO vs TMO, DHR, IDXX, A, WAT
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
9.50 | 1.28B | 727.33M | -108.03M | -21.78M | -0.844 |
|
TMO
Thermo Fisher Scientific Inc
|
508.58 | 195.79B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
206.00 | 148.95B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
636.70 | 52.44B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
118.17 | 34.33B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
307.23 | 31.33B | 3.17B | 642.63M | 516.49M | 10.77 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-30 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-07-29 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | 開始されました | Guggenheim | Neutral |
| 2025-04-30 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2024-12-10 | 開始されました | Jefferies | Buy |
| 2024-05-01 | 再開されました | Craig Hallum | Buy |
| 2023-12-29 | 繰り返されました | BTIG Research | Buy |
| 2023-08-21 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | アップグレード | BTIG Research | Neutral → Buy |
| 2023-02-24 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-02-01 | アップグレード | Needham | Hold → Buy |
| 2022-08-26 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2022-08-22 | ダウングレード | Needham | Buy → Hold |
| 2022-06-03 | 開始されました | Piper Sandler | Overweight |
| 2022-03-29 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-29 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | 再開されました | Stephens | Overweight |
| 2021-12-16 | 開始されました | Cowen | Outperform |
| 2021-11-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | 開始されました | Goldman | Buy |
| 2021-02-25 | 再開されました | Needham | Buy |
| 2021-02-25 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | 開始されました | Truist | Buy |
| 2020-12-11 | 再開されました | BTIG Research | Buy |
| 2020-10-28 | 繰り返されました | Needham | Buy |
| 2020-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2020-08-28 | 開始されました | Guggenheim | Buy |
| 2020-07-29 | 繰り返されました | Needham | Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Buy |
| 2020-04-21 | 再開されました | Stephens | Overweight |
| 2020-03-02 | 再開されました | Craig Hallum | Buy |
| 2020-02-28 | アップグレード | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | ダウングレード | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | 繰り返されました | Needham | Buy |
| 2019-05-01 | 繰り返されました | Needham | Buy |
| 2019-03-29 | 繰り返されました | Needham | Buy |
| 2019-01-03 | 開始されました | Needham | Buy |
| 2018-10-24 | アップグレード | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | 開始されました | Leerink Partners | Outperform |
| 2018-05-02 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | ダウングレード | BTIG Research | Buy → Neutral |
| 2017-08-24 | 開始されました | Gabelli & Co | Buy |
| 2016-12-15 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Neogenomics Inc (NEO) 最新ニュース
Natera, NeoGenomics Unit End Patent Suit Over Lung Cancer Test - Bloomberg Law News
3 Reasons to Avoid NEO and 1 Stock to Buy Instead - Finviz
(NEO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tu - PharmiWeb.com
NeoGenomics Launches RaDaR ST Molecular Residual Disease Test - marketscreener.com
NeoGenomics, Inc. Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types - marketscreener.com
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types - The Joplin Globe
NeoGenomics outlines $793M–$801M 2026 revenue target as RaDaR ST and PanTracer initiatives gain traction - MSN
NeoGenomics, Inc. Experiences Revision in Its Stock Evaluation Amid Mixed Financial Indicators - Markets Mojo
5 Insightful Analyst Questions From NeoGenomics's Q4 Earnings Call - Finviz
NeoGenomics, Inc. (NEO) Stock Analysis: A 47% Upside Potential in the Healthcare Diagnostics Sector - DirectorsTalk Interviews
Market Catalysts: What are Calix Incs technical support levelsMarket Trend Report & Verified Momentum Watchlists - baoquankhu1.vn
5 Insightful Analyst Questions From NeoGenomics’s Q4 Earnings Call - TradingView
NeoGenomics (NEO) Q4 2025 Earnings Call Transcript - AOL.com
NeoGenomics, Inc. (NASDAQ:NEO) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
NeoGenomics (NASDAQ:NEO) Gains Traction In Nasdaq Index Mid-Cap Healthcare - Kalkine Media
Assessing NeoGenomics (NEO) Valuation After Recent Share Price Weakness - Yahoo Finance
NeoGenomics, Inc. $NEO Shares Bought by White Pine Capital LLC - MarketBeat
NeoGenomics, Inc. $NEO Stock Holdings Lifted by Aberdeen Group plc - MarketBeat
Short Squeeze: What is the PEG ratio of Brookdale Senior Living IncStock Surge & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
After Plunging 22.8% in 4 Weeks, Here's Why the Trend Might Reverse for NeoGenomics (NEO) - Finviz
NeoGenomics to Participate in the 20th Annual Needham Virtual Healthcare Conference - ACCESS Newswire
Why is NeoGenomics Inc. stock going upM&A Rumor & Free High Accuracy Swing Entry Alerts - mfd.ru
UBS Maintains Hold on NeoGenomics, Inc. (NEO) on Feb 18, 2026 - Meyka
Needham & Company LLC Forecasts Strong Price Appreciation for NeoGenomics (NASDAQ:NEO) Stock - Defense World
NeoGenomics Q4 Earnings Call Highlights - Defense World
NeoGenomics Faces High-Stakes Risk as Test Reliability and Diagnostic Errors Threaten Reputation and Legal Exposure - TipRanks
NeoGenomics (NASDAQ:NEO) Trading Down 8.9%Should You Sell? - MarketBeat
NeoGenomics (NEO) Stock Drops After 2026 Outlook Misses ExpectationsNews and Statistics - IndexBox
Weekly Trades: Will ChoiceOne Financial Services Inc benefit from green energy policies2025 Performance Recap & Fast Moving Market Watchlists - baoquankhu1.vn
Why NeoGenomics (NEO) Shares Are Falling Today - Finviz
NeoGenomics, Inc. (NASDAQ:NEO) Q4 2025 Earnings Call Transcript - Insider Monkey
NeoGenomics to Participate in Upcoming Investor Conferences - The Joplin Globe
NEO Q4 Deep Dive: Product Mix Shift and Guidance Weigh on Outlook - Finviz
NeoGenomics Q4 2025 slides: 11% revenue growth, RaDaR ST launch imminent - Investing.com South Africa
Labcorp (LH) Q4 2025 Earnings Call Transcript - AOL.com
NeoGenomics PanTracer Pro Launch Adds New Dimension To Growth Story - Yahoo Finance
NeoGenomics Earnings Call Signals Growth With Caveats - TipRanks
Needham raises Neogenomics stock price target on 2027 estimates - Investing.com Australia
Needham raises Neogenomics stock price target on 2027 estimates By Investing.com - Investing.com South Africa
NeoGenomics (NASDAQ:NEO) Shares Gap DownTime to Sell? - MarketBeat
NeoGenomics Q4 2025 Earnings Call Transcript - MarketBeat
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results - BioSpace
NeoGenomics, Inc. (NEO) Investor Outlook: Assessing The 27.97% Potential Upside - DirectorsTalk Interviews
Earnings call transcript: NeoGenomics Q4 2025 earnings beat expectations - Investing.com
NeoGenomics shares fall over 5% despite earnings beat By Investing.com - Investing.com Canada
NeoGenomics: Q4 Earnings Snapshot - KVUE
NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
Neogenomics Inc (NEO) 財務データ
収益
当期純利益
現金流量
EPS
0.78%
大文字化:
|
ボリューム (24 時間):